医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

ENHERTU

ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer

ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer

ヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: ENHERTU in Patients with HER2 Positive Metastatic Breast Cancer Reduced the T-DM Versus Trastuzumab Emtansine

2021年09月18日

ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU Trial

2021年09月18日

ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer

ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer

ヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: ENHERTU in Patients with HER2 Positive Metastatic Breast Cancer Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus Trastuzumab Emtansine T-DM

2021年08月09日

ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU

2021年01月20日

ADDING MULTIMEDIA — ENHERTU® Approved in the U.S. for the Treatment of Patients with Previously Treated HER2 Positive Advanced Gastric Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ADDING MULTIMEDIA ENHERTU

2021年01月18日

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU

2021年01月16日

ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive Metastatic Breast Cancer

ヘルスケア腫瘍学臨床試験製薬　 TimeLine: Continues to Demonstrate Durable Responses with ENHERTU from DESTINY-Breast01 in HER2 Positive Metastatic Breast Cancer

2020年12月10日

ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer

その他ヘルスヘルスケアヘルス一般腫瘍学臨床試験製薬遺伝学　 TimeLine: ENHERTU

2020年09月25日

ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial

ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial

ヘルスケア腫瘍学臨床試験製薬　 TimeLine: DESTINY-Gastric01 Trial ENHERTU Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase

2020年05月29日

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase DESTINY-Lung01 Trial ENHERTU

2020年05月29日